• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Everolimus

Everolimus

Product ID E8419
Cas No. 159351-69-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $61.10 In stock
5 mg $137.90 In stock
25 mg $330.80 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Everolimus is an inhibitor of mammalian target of rapamycin 1 (mTOR1) that is used clinically for its immunosuppressive activity in renal transplant recipients and is currently in clinical trials exploring its anticancer chemotherapeutic activity. In nasopharyngeal carcinoma cells, everolimus induces apoptosis and autophagy, inhibiting cell growth. In esophageal cancer cells, everolimus decreases expression of mTOR targets p70S6K and S6, increasing cell damage and decreasing cell proliferation. In animal models of experimental autoimmune uveoretinitis (EAU), everolimus decreases levels of Th1, Th2, and Th17 cytokines and increases levels of Treg cells, attenuating disease pathology. Additionally, everolimus exhibits nephroprotective benefit at low doses, decreasing adriamycin-induced proteinuria and improving renal function in animal models of nephrotic syndrome.

Product Info

Cas No.

159351-69-6

Purity

≥98%

Formula

C53H83NO14

Formula Wt.

958.22

Chemical Name

40-O-(2-hydroxyethyl)-sirolimus

IUPAC Name

Dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0 hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

Synonym

Certican, SDZ RAD, 40-O-(2-hydroxyethyl)-rapamycin, RAD001

Melting Point

95-110°C

Solubility

Insoluble in water. Soluble in DMSO (30mg/mL), ethanol (7 mg/mL).

Appearance

White to off white powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

E8419 MSDS PDF

Info Sheet

E8419 Info Sheet PDF

Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Sendur MA, Zengin N, Aksoy S, et al. Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin. 2014 Jan;30(1):75-87. PMID: 24050600.

Cai Y, Xia Q, Su Q, et al. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells. Int J Mol Med. 2013 Apr;31(4):904-12. PMID: 23426850.

Hennig M, Bauer D, Wasmuth S, et al. Everolimus improves experimental autoimmune uveoretinitis. Exp Eye Res. 2012 Dec;105:43-52. PMID: 23059401.

Ramadan R, Faour D, Awad H, et al. Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome. Nephrol Dial Transplant. 2012 Jun;27(6):2231-41. PMID: 22036940.

Wang ZG, Fukazawa T, Nishikawa T, et al. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncol Rep. 2010 Apr;23(4):1167-72. PMID: 20204306.

Kahan BD, Koch SM. Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care. 2001 Aug;7(4):242-50. PMID: 11571421.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E5214

    α-Endorphin

    Endogenous opioid peptide; μOR agonist.

    ≥95%
  • A9801

    Azaperone

    Butyrophenone; α-adrenergic, D2, histamine ant...

    ≥98%
  • K0652

    Kb NB 142-70

    PKD inhibitor.

    ≥98%
  • L8261

    Lupeol

    Triterpene; potential tyrosinase inhibitor.

    ≥98%
  • W0247

    Walrycin B

    Walrycin response regulator inhibitor.

    ≥98%
  • Q8135

    Quinestrol

    Synthetic steroid hormone, estrogen analog, use...

    ≥98%
  • P0146

    Palmitoyl-L-carnitine

    Long chain acylcarnitine involved in fatty acid...

    ≥98%
  • S0929

    SCH-772984

    ERK1/2 inhibitor.

    ≥97%
  • K977545

    Kynurenic acid

    Endogenous NMDA receptor antagonist.

    ≥99%
  • C0252

    Canertinib Dihydrochloride

    EGFR inhibitor.

    ≥98%
  • A081014

    Acalabrutinib

    Inhibitor of Bruton’s tyrosine kinase (BTK).<...

    ≥99%
  • P1854

    Penicillic Acid

    Neuroactive mycotoxin produced by Penicillum an...

    ≥98%
  • K1655

    Kenpaullone

    GSK-3β, HGK, and CDK inhibitor.

    ≥95%
  • M400005

    MK-5108 Hydrochloride

    Aurora kinase A inhibitor.

    ≥98%
  • I7457

    1-Isothiocyanato-6-(methylsulfinyl)-hexane

    Synthetic derivative of 6-methylsulfinyl-hexane...

    ≥98%
  • S1069

    Scriptaid

    HDAC inhibitor.

    ≥98%
  • G5752

    Gonadorelin Acetate

    Synthetic peptide, GnRH derivative; GnRH agonist.
    ≥95%
  • J023736

    (±)-Jasmonic Acid

    Phytohormone

    ≥98% (sum of isomers)
  • O7332

    OSI-027

    mTOR inhibitor.

    ≥99%
  • G1975

    Gestrinone

    Synthetic steroid hormone; AR agonist, ER and P...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only